Phase 1/2 × Lymphoma × Gastrointestinal × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
NCT02431260 2019-06-14

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
69 enrolled 34 charts